Evaluation of acetylator phenotype of isoniazid among tuberculosis patients in delta state Nigeria: update on management of toxicity

Clinical Prediction of Acetylator Phenotype in Tuberculosis Patients on Medicare using Blood Group

“…As a result, determining individual acetylator status prior to the administration of treatment regime would be an effective strategy towards curbing with incidences of hepatotoxicity and adverse side effects experienced by Tb patients undergoing treatment in various centers. Incidentally, every patient in the population is still being treated in a similar manner without pathology-based evidence as if they are all of the same acetylator status (Nwose et al 2016). As clearly put by some authors, acetylation phenotype is yet to be on the post-treatment or pre-treatment laboratory testing list (add-on-test); probably because there is still controversy over the necessity of acetylation monitoring including the role of genetics (Azuma et al, 2013, Hayashi et al, 2015, Jung et al, 2015.…”

“…As clearly put by some authors, acetylation phenotype is yet to be on the post-treatment or pre-treatment laboratory testing list (add-on-test); probably because there is still controversy over the necessity of acetylation monitoring including the role of genetics (Azuma et al, 2013, Hayashi et al, 2015, Jung et al, 2015. Though, numerous studies have reported how individual genetic profile may be relevant in adjusting drug dosages and selecting medications (Bachtiar et al, 2019), adopting this knowledge will be useful in tailoring individual dosing to minimize side effects and maximize clinical outcomes (Patin et al, 2006, Nwose et al 2016, Richardson et al, 2019. Conclusion Blood groups have been widely studied as Mendalian traits across populations, however, the predictive clinical use of blood group as a possible alternative technique for determining acetylators phenotypes in Tb patients may not be feasible in the interim.…”